Advances in DLL3-targeted therapies for small cell lung cancer: challenges, opportunities, and future directions
Small cell lung cancer (SCLC) remains one of the most aggressive and challenging malignancies to treat, with limited therapeutic options and poor outcomes. Recent advances in understanding SCLC biology have identified Delta-like ligand 3 (DLL3) as a promising target for novel therapies. This review...
Salvato in:
| Autori principali: | , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Frontiers Media S.A.
2024-12-01
|
| Serie: | Frontiers in Oncology |
| Soggetti: | |
| Accesso online: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1504139/full |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|